Infusion of neutrophil precursors for treatment of neutropenia
US6010697A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 27, 1998 |
| Grant date | Jan 4, 2000 |
| Priority date | — |
| Expiry date | Aug 27, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/39
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method of treating a patient having a reduced population of neutrophils following a myeloablative cancer treatment such as high dose chemotherapy. Following myeloablative therapy, a cell composition of at least 25% neutrophil precursors, i.e. promyelocytes, myelocytes, and metamyelocytes, is administered to the patient. Thereafter, the neutrophil precursors differentiate rapidly in vivo to replenish the supply of mature neutrophils for fighting infection. The method is used to reduce the neutropenic window between the time of myeloablative therapy and the time required for infused stem cells to proliferate and differentiate into mature neutrophils.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.